June 2018 - Volume 28 - Issue 3 - Contributor Index

Alphabetical Search
A
Q
W
X
Y
Z
Author:
Balada, Ariadna

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Bañuls, José
Author:
Barysch, Marjam

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Author:
Batty, Nicolas

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Author:
Baum, Mary

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Author:
Braun, Ralph

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Author:
Chesney, Jason

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Author:
Cortes, Javier

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Author:
Falo, Louis D.
Author:
Fraig, Mostafa

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Author:
Franzen, Daniel

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Author:
Joosse, Arjen

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Mangana, Joanna

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Moll, Iris
Author:
Montagut, Clara

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Muñoz, Eva

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Author:
Nagore, Eduardo

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Puig, Susana
Author:
Ranjan, Smita

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Author:
Requena, Celia

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Rosell, Rafael

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Soria, Ainara

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

Author:
Suciu, Stefan

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Author:
Sucker, Antje
Author:
Suppa, Mariano

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Author:
Telang, Sucheta

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

Testori, Alessandro A.; Suciu, Stefan; van Akkooi, Alexander C.J.; More

Melanoma Research. 28(3):222-229, June 2018.

Show: